Macquarie Group
CYTK icon

Macquarie Group’s Cytokinetics CYTK Stock Holding History

Macquarie Group’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-110,260
Closed -$6.06M – 1018
2025
Q3 		$6.06M Buy
110,260
+26,388
+31% +$1.09M 0.01% 918
2025
Q2 		$2.77M Buy
83,872
+9,466
+13% +$329K ﹤0.01% 1136
2025
Q1 		$2.99M Sell
74,406
-1,027
-1% -$47.2K ﹤0.01% 1108
2024
Q4 		$3.55M Buy
75,433
+1,533
+2% +$79.6K ﹤0.01% 1026
2024
Q3 		$3.9M Buy
73,900
+301
+0.4% +$16.8K ﹤0.01% 1034
2024
Q2 		$3.99M Sell
73,599
-27,445
-27% -$1.66M ﹤0.01% 1030
2024
Q1 		$7.08M Buy
101,044
+59,060
+141% +$4.57M 0.01% 886
2023
Q4 		$3.5M Sell
41,984
-5,775
-12% -$209K ﹤0.01% 1061
2023
Q3 		$1.41M Buy
47,759
+9,059
+23% +$302K ﹤0.01% 1261
2023
Q2 		$1.26M Buy
38,700
+2,276
+6% +$84.2K ﹤0.01% 1312
2023
Q1 		$1.28M Sell
36,424
-37,236
-51% -$1.52M ﹤0.01% 1302
2022
Q4 		$3.38M Sell
73,660
-40,645
-36% -$1.75M ﹤0.01% 1057
2022
Q3 		$5.58M Buy
114,305
+34,847
+44% +$1.68M 0.01% 964
2022
Q2 		$3.12M Buy
79,458
+28,156
+55% +$1.13M ﹤0.01% 1151
2022
Q1 		$1.89M Buy
51,302
+5,655
+12% +$201K ﹤0.01% 1384
2021
Q4 		$2.08M Sell
45,647
-15,316
-25% -$591K ﹤0.01% 1364
2021
Q3 		$2.18M Sell
60,963
-13,636
-18% -$401K ﹤0.01% 1362
2021
Q2 		$1.48M Sell
74,599
-160
-0.2% -$3.76K ﹤0.01% 1506
2021
Q1 		$1.74M Buy
74,759
+4,469
+6% +$95.4K ﹤0.01% 1246
2020
Q4 		$1.46M Buy
70,290
+68,333
+3,492% +$1.25M ﹤0.01% 1200
2020
Q3 		$42K Hold
1,957
– – ﹤0.01% 1992
2020
Q2 		$46K Buy
+1,957
New +$36.7K ﹤0.01% 1955
2018
Q1 		– Sell
-900
Closed -$7K – 2210
2017
Q4 		$7K Buy
+900
New +$10.2K ﹤0.01% 2329

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Macquarie Group's CYTK Position: Q4 2025 in Review

Macquarie Group sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 110,260 shares — an estimated $6.06M sold.

Macquarie Group first reported a position in CYTK in Q4 2017 and held it in 23 quarters. The position peaked at $7.08M in Q1 2024. 430 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Macquarie Group reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Macquarie Group sold 110,260 Cytokinetics shares in Q4 2025, an estimated $6.06M.
  • Macquarie Group first reported a position in Cytokinetics in Q4 2017 and held it in 23 quarters.
  • Macquarie Group's Cytokinetics position peaked at $7.08M in Q1 2024.
  • 430 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Macquarie Group's 13F filing for Q4 2025, filed 13 Feb 2026.